BNP Paribas Financial Markets
LXEO icon

BNP Paribas Financial Markets’s Lexeo Therapeutics LXEO Stock Holding History

BNP Paribas Financial Markets’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.31M Sell
228,201
-29,216
-11% -$207K ﹤0.01% 2952
2025
Q4 		$2.56M Buy
257,417
+226,690
+738% +$2.07M ﹤0.01% 2469
2025
Q3 		$204K Sell
30,727
-17,707
-37% -$85.6K ﹤0.01% 4004
2025
Q2 		$195K Buy
48,434
+8,223
+20% +$27K ﹤0.01% 3777
2025
Q1 		$140K Buy
40,211
+5,684
+16% +$25.2K ﹤0.01% 3902
2024
Q4 		$227K Buy
34,527
+28,986
+523% +$228K ﹤0.01% 3793
2024
Q3 		$50.1K Buy
5,541
+3,591
+184% +$42.8K ﹤0.01% 3612
2024
Q2 		$31.3K Sell
1,950
-2,831
-59% -$41.1K ﹤0.01% 3571
2024
Q1 		$75K Buy
+4,781
New +$74.8K ﹤0.01% 3504

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BNP Paribas Financial Markets's LXEO Position: Q1 2026 in Review

BNP Paribas Financial Markets reduced its Lexeo Therapeutics (LXEO) stake by 11% in Q1 2026, selling an estimated $207K and leaving 228,201 shares worth $1.31M. The position accounts for ﹤0.01% of the portfolio, ranked #2952.

BNP Paribas Financial Markets first reported a position in LXEO in Q1 2024 and has held it in 9 quarters since. The position peaked at $2.56M in Q4 2025. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • BNP Paribas Financial Markets held 228,201 shares of Lexeo Therapeutics worth $1.31M as of Q1 2026.
  • BNP Paribas Financial Markets sold 29,216 Lexeo Therapeutics shares in Q1 2026, an estimated $207K.
  • Lexeo Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #2952 holding.
  • BNP Paribas Financial Markets first reported a position in Lexeo Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • BNP Paribas Financial Markets's Lexeo Therapeutics position peaked at $2.56M in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.